We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CV Biomarkers Associated with Incident Heart Failure

By LabMedica International staff writers
Posted on 12 Apr 2018
Print article
Image: A diagram of two different forms of heart failure compared with a normal heart (Photo courtesy of The Medical University of South Carolina).
Image: A diagram of two different forms of heart failure compared with a normal heart (Photo courtesy of The Medical University of South Carolina).
Nearly half of all patients with heart failure have preserved ejection fraction as opposed to reduced ejection fraction, yet associations of biomarkers with future heart failure subtype are incompletely understood.

Heart failure with preserved ejection fraction (HFpEF) is a form of congestive heart failure where in the amount of blood pumped from the heart's left ventricle with each beat (ejection fraction) is greater than 50%. Heart failure with reduced ejection fraction (HFrEF) happens when the left side of your heart does not pump blood out to the body as well as normal.

A large team of international scientists collaborating with the University Medical Centre Groningen (Groningen, the Netherlands) enrolled 22,756 participants in four longitudinal community-based cohorts, and measured several biomarkers of renal dysfunction, endothelial dysfunction, and inflammation, in addition to natriuretic peptides and high-sensitivity troponin.

The following biomarkers were examined: N-terminal pro B-type natriuretic peptide or brain natriuretic peptide, high-sensitivity troponin T or I (cTn), C-reactive protein (CRP), urinary albumin to creatinine ratio (UACR), renin to aldosterone ratio, D-dimer, fibrinogen, soluble suppressor of tumorigenicity, galectin-3, cystatin C, plasminogen activator inhibitor 1, and interleukin 6.

Among the 22 756 participants in these four cohorts there were 12, 087 women and 10,669 men; mean age, 60 ±13 years, in the study, during a median follow-up of 12 years, 633 participants developed incident HFpEF, and 841 developed HFrEF. Two biomarkers were significantly associated with incident HFpEF: UACR and natriuretic peptides; with suggestive associations for high-sensitivity troponin. In contrast, six biomarkers reflecting renal dysfunction, endothelial dysfunction, and inflammation were associated with incident HFrEF, including natriuretic peptides, UACR, cTn, cystatin C, D-dimer, and CRP. When directly compared, natriuretic peptides, high-sensitivity troponin, and CRP were more strongly associated with HFrEF compared with HFpEF.

The authors concluded that biomarkers of renal dysfunction, endothelial dysfunction, and inflammation were associated with incident HFrEF. By contrast, only natriuretic peptides and UACR were associated with HFpEF. These findings highlight the need for future studies focused on identifying novel biomarkers of the risk of HFpEF. The study was published on March 1, 2018, in the journal JAMA Cardiology.

Related Links:
University Medical Centre Groningen

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.